Home/Filings/4/0000950170-24-136391
4//SEC Filing

KARBE FRANK 4

Accession 0000950170-24-136391

CIK 0001783183other

Filed

Dec 15, 7:00 PM ET

Accepted

Dec 16, 8:05 AM ET

Size

5.0 KB

Accession

0000950170-24-136391

Insider Transaction Report

Form 4
Period: 2024-12-13
KARBE FRANK
Director
Transactions
  • Purchase

    Common Stock

    2024-12-13$7.93/sh+12,500$99,08457,000 total
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.87 to $8.00. The reporting person undertakes to provide Phathom Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Documents

1 file

Issuer

Phathom Pharmaceuticals, Inc.

CIK 0001783183

Entity typeother

Related Parties

1
  • filerCIK 0001276700

Filing Metadata

Form type
4
Filed
Dec 15, 7:00 PM ET
Accepted
Dec 16, 8:05 AM ET
Size
5.0 KB